| 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展 战略等情况，公司定于 2023 年 5 月 23 日（星期二）15:00-17:00 在"价值在线" （www.ir-online.cn）举行思创医惠科技股份有限公司 2022 年度网上业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。现将有关事项公 告如下： 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 5 月 23 日（星期二）15:00-17:00 会议召开地点 ...

思创医惠科技股份有限公司 2023 年第一季度报告 证券代码：300078 证券简称：思创医惠 公告编号：2023-041 债券代码：123096 债券简称：思创转债 思创医惠科技股份有限公司 3.第一季度报告是否经过审计 □是 否 1 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 思创医惠科技股份有限公司 2023 年第一季度报告 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 235,156,485.53 | 386,055,693.36 | -39.09 ...

Financial Performance - The company reported significant losses due to extended delivery cycles and increased costs, resulting in a substantial decline in performance [3]. - The company's operating revenue for 2022 was ¥1,108,893,359.21, representing a 15.32% increase compared to ¥961,549,939.60 in 2021 [27]. - The net profit attributable to shareholders was -¥881,508,508.17 in 2022, a decrease of 21.25% from -¥727,023,296.46 in 2021 [27]. - The cash flow from operating activities showed a net outflow of -¥105,192,708.38, a significant decline of 178.48% compared to a positive cash flow of ¥134,041,273.63 in 2021 [27]. - The total assets at the end of 2022 were ¥3,648,625,453.19, down 24.98% from ¥4,863,530,760.78 at the end of 2021 [27]. - The net assets attributable to shareholders decreased by 39.84% to ¥1,311,618,631.90 at the end of 2022 from ¥2,180,294,683.75 at the end of 2021 [27]. - The basic and diluted earnings per share for 2022 were both -¥1.06, a decline of 21.84% from -¥0.87 in 2021 [27]. - The company reported a quarterly revenue of ¥99,866,650.86 in Q4 2022, a significant drop compared to Q1 2022 revenue of ¥386,055,693.36 [29]. - The company experienced a net loss of -¥886,191,718.12 in Q4 2022, following a net profit of ¥30,953,691.43 in Q1 2022 [29]. - The company received government subsidies amounting to ¥11,530,082.86 in 2022, down from ¥18,849,936.02 in 2021 [33]. - The total non-recurring gains and losses for 2022 amounted to ¥18,921,990.29, a decrease from ¥75,592,354.95 in 2021 [34]. Business Focus and Innovation - The core business focuses on smart healthcare, leveraging IoT, big data, AI, and blockchain technologies, with services applied in over 1,600 medical institutions across China [6]. - The company has established over 10 technology innovation R&D centers and participated in more than 20 national major research projects [6]. - The company plans to continue focusing on innovation, differentiated products, and standardized systems to enhance customer experience [6]. - The smart healthcare industry in China is projected to reach an IT expenditure market size of CNY 104.15 billion by 2024, with a compound annual growth rate (CAGR) exceeding 15% for healthcare application software solutions [38]. - The company aims to leverage five core technologies—IoT, artificial intelligence, big data interaction, microservices architecture, and blockchain—to drive innovation in smart healthcare services [42]. - The company has developed a series of integrated clinical electronic medical record systems, enhancing operational efficiency in hospitals [43]. - The company is focusing on expanding its software solutions, including the Medical Data Visualization Engine System V1.0, to improve data accessibility [54]. - The company is committed to ongoing research and development, with a focus on innovative healthcare solutions [71]. Market Trends and Opportunities - The regional healthcare informationization market is projected to grow from RMB 46.6 billion in 2021 to RMB 124.5 billion by 2025, with a compound annual growth rate of 27.9% [7]. - The company has established long-term strategic partnerships with international firms such as Huawei, H3C, Baidu, and IBM, enhancing its position as a leading provider of smart healthcare solutions in China [42]. - The government has introduced multiple policies to promote the development of smart healthcare, creating new opportunities for the industry [40]. - The RFID industry in China is expected to grow significantly, with an estimated market value exceeding CNY 35 billion by 2025, following a decline in 2020 [47]. - The company is recognized as one of the top three global players in the RFID market, maintaining a leading market share for its basic and ultra-high frequency RFID products [48]. Research and Development - The company invested a total of 203.77 million yuan in R&D, accounting for 18.38% of its operating revenue [63]. - The company has obtained a total of 7 invention patents, 38 utility model patents, and 13 design patents during the reporting period, showcasing its commitment to innovation [68]. - The company has launched new products such as the intelligent anti-theft management system and health cloud platform, enhancing its product portfolio [71]. - The company has developed over 60 single-disease data resource libraries and applications based on its THINKGO medical AI cognitive engine [74]. - The company has completed the development of a Bluetooth-enabled temperature monitoring system, aimed at improving product competitiveness in the wearable device market [112]. Strategic Partnerships and Collaborations - The company has established long-term stable partnerships with over 300 clients and agents, exporting products to more than 70 countries and regions, including Europe, America, the Middle East, and Southeast Asia [49]. - The company is actively pursuing strategic acquisitions to enhance its technological capabilities and market reach [71]. - The company has formed a strategic partnership with Yunhai Chain Holdings to integrate smart medical services with blockchain technology [150]. - The company emphasizes collaboration with various healthcare partners to create an inclusive and open ecosystem for smart healthcare services [155]. Corporate Governance and Management - The company has no controlling shareholder or actual controller, maintaining independence in operations, assets, and finances [175]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal requirements for governance structure [176]. - The supervisory board held 8 meetings during the reporting period, overseeing major transactions and ensuring compliance with regulations [178]. - The company has established a fair and effective performance evaluation and incentive mechanism for senior management, combining base salary with annual performance assessments [179]. - The company strictly adheres to information disclosure obligations, ensuring timely and accurate reporting of financial and operational information [180]. Challenges and Risks - The company faces intensified competition in the IoT and smart healthcare sectors, necessitating continuous technological advancements and market expansion strategies to maintain its competitive edge [158]. - The company is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, which may impact its operations and reputation [169]. - The company is actively managing foreign exchange risks due to significant export proportions in its business, employing suitable hedging tools and insurance to mitigate potential losses [163]. Future Outlook - The company aims to enhance its market presence through the introduction of new products and technologies in the healthcare sector [30]. - The company is strategically positioning itself for future growth by expanding its software capabilities and exploring new market opportunities [62]. - The company is committed to improving its research and development capabilities to keep pace with rapid technological advancements in the healthcare industry [159].

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |----------------|-----------------------|------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 普尔投资 | | | 人员姓名 | | 执行董事兼研究主管：朱一峰 | | 时间 | 2015 年 12 | 日 | | 地点 | 杭州市莫干山路 | 1418-48 号 | | 上市公司接待人 | 副总经理兼董秘 周为利 | | | 员姓名 | 证券事务助理 季仕才 | | | 投资者关系活动 | | 一、来访投资者签署《承诺书》 | | 主要内容介绍 | | 二、公司目前的智慧医疗业务和未来的发展方向介绍 | | | ...

编号：2014-07 证券代码：300078 证券简称：中瑞思创 杭州中瑞思创科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 招商证券 罗聪 | | | 人员姓名 | | | | 时间 | 2014 年 12 月 05 | 日下午 2:00-3:00 | | 地点 | 杭州市莫干山路 | 1418-48 号公司五楼会议室 | | 上市公司接待人 | 董事会秘书 陈武军先生 | | | 员姓名 | 证券事务助理 杨小芬女士 | | | 投资者关系活动 | 一、 | 与会投资者签署《承诺书》 | | 主要内容介绍 | 二 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |----------------|------------------------|----------------------------------------| | | | | | | | | | | | √特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | | 工银瑞信基金 | | | | | 投资副总兼基金经理：何肖颉/胡文彪/张青 | | | | 研究副总：王君正 | | | 基金经理兼 | TMT 组长：贾晓新 | | 参与单位名称及 | | 基金经理：修世宇/鄢耀 | | 人员姓名 | | 投资经理：李劭钊 | | | 研究员：夏雨 | | | | 中金公司 | | | | 分析员：张景松 | | | 时间 | 2015 年 12 月 | 15 日 | | 地点 | 医惠科技会议室 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0608 | --- | --- | --- | |----------------|-----------------------------|-----------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 国泰君安：王 喆 方正证券：王彬彬 常春藤资产：饶海宁 | | | | 平安资产：叶 青 未域资产：王颖羚 人保资产：李明杰 | | 参与单位名称及 | | 弘尚资产：赵 杰 金库骐楷（杭州）投资：金伟彪 蔡宜韬 | | 人员姓名 | | 深圳前海安康投资：裘一凯 哲云投资：朱锴沣 丁谢峰 | | | | 物产中大资本：郑秀峰 上海泊通投资：庒 臣 | | 时间 | 2016 年 6 月 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0405 | --- | --- | --- | |----------------|------------------------|--------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 野村证券（香港）：黄乐平、段冰、唐圣波、 Zoe Chow ；安 | | | | 联投资：叶子君；未来资产：刘伟康、许靖茹；摩根士丹利投 | | 参与单位名称及 | | 资： 张嘉行；中银保诚基金：周原；三井住友资产：陈梓 | | 人员姓名 | 豪、李育文；上投摩根： | Howard Zhou ；浮尔顿资产： | | | Yuxuan Wang | ；嘉实基金：左久；凯斯博基金： Raymo ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0203 | --- | --- | --- | --- | |----------------|-----------------------|-------------------------------------|------------------------------------------------| | | | | | | | √ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | | 广发证券：计算机行业分析师 王文龙 王奇钰 | | | | 中泰证券：计算机行业研究员 李振亚 | | | 参与单位名称及 | | 计算机行业分析师 方闻千 | | | 人员姓名 | | 泰旸资产：高级研究员 赖燊生 | | | | | 浙江新干线传媒投资：投资经理 阮继祥 | | | 时间 | ...